Covalently closed circular DNA: The ultimate therapeutic target for curing HBV infections

Isorce, 2015, Immune-modulators to combat hepatitis B virus infection: from IFN-α to novel investigational immunotherapeutic strategies, Antiviral Res, 122, 69, 10.1016/j.antiviral.2015.08.008 Gish, 2012, Selection of chronic hepatitis B therapy with high barrier to resistance, Lancet Infect Dis, 12, 341, 10.1016/S1473-3099(11)70314-0 Cornberg, 2020, 2019 EASL-AASLD HBV treatment endpoints conference faculty. Guidance for design and endpoints of clinical trials in chronic hepatitis B - report from the 2019 EASL-AASLD HBV treatment endpoints conference‡, J Hepatol, 72, 539, 10.1016/j.jhep.2019.11.003 Lebossé, 2020, Quantification and epigenetic evaluation of the residual pool of hepatitis B covalently closed circular DNA in long-term nucleoside analogue-treated patients, Sci Rep, 10, 21097, 10.1038/s41598-020-78001-1 Lai, 2017, Reduction of covalently closed circular DNA with long-term nucleos(t)ide analogue treatment in chronic hepatitis B, J Hepatol, 66, 275, 10.1016/j.jhep.2016.08.022 Lai, 2020, Rebound of HBV DNA after cessation of nucleos/tide analogues in chronic hepatitis B patients with undetectable covalently closed circular DNA, JHEP Rep, 2, 100112, 10.1016/j.jhepr.2020.100112 Nassal, 2015, HBV cccDNA: viral persistence reservoir and key obstacle for a cure of chronic hepatitis B, Gut, 64, 1972, 10.1136/gutjnl-2015-309809 Hu, 2015, Hepadnavirus genome replication and persistence, Cold Spring Harb Perspect Med, 5, a021386, 10.1101/cshperspect.a021386 Tu, 2018, Hepatitis B virus DNA integration occurs early in the viral life cycle in an in vitro infection model via sodium taurocholate cotransporting polypeptide-dependent uptake of enveloped virus particles, J Virol, 92, e02007, 10.1128/JVI.02007-17 Ali, 2014, Hepatitis B virus, HBx mutants and their role in hepatocellular carcinoma, WJG, 20, 10238, 10.3748/wjg.v20.i30.10238 Wooddell, 2017, RNAi-based treatment of chronically infected patients and chimpanzees reveals that integrated hepatitis B virus DNA is a source of HBsAg, Sci Transl Med, 9, 10.1126/scitranslmed.aan0241 Yan, 2012, Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus, ELife, 1, 10.7554/eLife.00049 Königer, 2014, Involvement of the host DNA-repair enzyme TDP2 in formation of the covalently closed circular DNA persistence reservoir of hepatitis B viruses, Proc Natl Acad Sci USA, 111, E4244, 10.1073/pnas.1409986111 Cui, 2015, Does tyrosyl DNA phosphodiesterase-2 play a role in hepatitis B virus genome repair?, PloS One, 10, 10.1371/journal.pone.0128401 Winer, 2017, Long-term hepatitis B infection in a scalable hepatic co-culture system, Nat Commun, 8, 125, 10.1038/s41467-017-00200-8 Cai, 2020, Characterization of the termini of cytoplasmic hepatitis B virus deproteinated relaxed circular DNA, J Virol, 95, 10.1128/JVI.00922-20 Qi, 2016, DNA polymerase κ is a key cellular factor for the formation of covalently closed circular DNA of hepatitis B virus, Plos Pathog, 12, 10.1371/journal.ppat.1005893 Tang, 2019, DNA Polymerase alpha is essential for intracellular amplification of hepatitis B virus covalently closed circular DNA, Plos Pathog, 15, 10.1371/journal.ppat.1007742 Long, 2017, The role of host DNA ligases in hepadnavirus covalently closed circular DNA formation, Plos Pathog, 13 Kitamura, 2018, Flap endonuclease 1 is involved in cccDNA formation in the hepatitis B virus, Plos Pathog, 14, 10.1371/journal.ppat.1007124 Wei, 2020, Core components of DNA lagging strand synthesis machinery are essential for hepatitis B virus cccDNA formation, Nat Microbiol, 5, 715, 10.1038/s41564-020-0678-0 Wei, 2021, Hepatitis B virus cccDNA is formed through distinct repair processes of each strand, Nat Commun, 12, 1591, 10.1038/s41467-021-21850-9 Boyd, 2016, Decay of ccc-DNA marks persistence of intrahepatic viral DNA synthesis under tenofovir in HIV-HBV co-infected patients, J Hepatol, 65, 683, 10.1016/j.jhep.2016.05.014 Bock, 1994, Hepatitis B virus genome is organized into nucleosomes in the nucleus of the infected cell, Virus Genes, 8, 215, 10.1007/BF01703079 Bock, 2001, Structural organization of the hepatitis B virus minichromosome, J Mol Biol, 307, 183, 10.1006/jmbi.2000.4481 Belloni, 2009, Nuclear HBx binds the HBV minichromosome and modifies the epigenetic regulation of cccDNA function, Proc Natl Acad Sci USA, 106, 19975, 10.1073/pnas.0908365106 Tropberger, 2015, Mapping of histone modifications in episomal HBV cccDNA uncovers an unusual chromatin organization amenable to epigenetic manipulation, Proc Natl Acad Sci USA, 112, E5715, 10.1073/pnas.1518090112 Protzer, 2015, Epigenetic control of HBV by HBx protein—releasing the break?, Nat Rev Gastroenterol Hepatol, 12, 558, 10.1038/nrgastro.2015.152 Bernstein, 2007, The mammalian epigenome, Cell, 128, 669, 10.1016/j.cell.2007.01.033 Pollicino, 2006, Hepatitis B virus replication is regulated by the acetylation status of hepatitis B virus cccDNA-bound H3 and H4 histones, Gastroenterology, 130, 823, 10.1053/j.gastro.2006.01.001 Hong, 2017, Epigenetic regulation of hepatitis B virus covalently closed circular DNA: implications for epigenetic therapy against chronic hepatitis B: Hong, Kim, and Guo, Hepatology, 66, 2066, 10.1002/hep.29479 Tu, 2020, De novo synthesis of Hepatitis B virus nucleocapsids is dispensable for the maintenance and transcriptional regulation of cccDNA, JHEP Rep, 100195 Lucifora, 2011, Hepatitis B virus X protein is essential to initiate and maintain virus replication after infection, J Hepatol, 55, 996, 10.1016/j.jhep.2011.02.015 Rivière, 2015, HBx relieves chromatin-mediated transcriptional repression of hepatitis B viral cccDNA involving SETDB1 histone methyltransferase, J Hepatol, 63, 1093, 10.1016/j.jhep.2015.06.023 Brown, 2015, Ubiquitylation, neddylation and the DNA damage response, Open Biol, 5, 150018, 10.1098/rsob.150018 Murphy, 2016, Hepatitis B virus X protein promotes degradation of SMC5/6 to enhance HBV replication, Cell Rep, 16, 2846, 10.1016/j.celrep.2016.08.026 Decorsière, 2016, Hepatitis B virus X protein identifies the Smc5/6 complex as a host restriction factor, Nature, 531, 386, 10.1038/nature17170 Niu, 2017, The Smc5/6 complex restricts HBV when localized to ND10 without inducing an innate immune response and is counteracted by the HBV X protein shortly after infection, PloS One, 12, 10.1371/journal.pone.0169648 Stadelmayer, 2020, Full-length 5’RACE identifies all major HBV transcripts in HBV-infected hepatocytes and patient serum, J Hepatol, 73, 40, 10.1016/j.jhep.2020.01.028 Kim, 2011, Replicative activity of hepatitis B virus is negatively associated with methylation of covalently closed circular DNA in advanced hepatitis B virus infection, Intervirology, 54, 316, 10.1159/000321450 Zhang, 2014, Transcription of hepatitis B virus covalently closed circular DNA is regulated by CpG methylation during chronic infection, PloS One, 9 Lutgehetmann, 2010, In vivo proliferation of hepadnavirus-infected hepatocytes induces loss of covalently closed circular DNA in mice, Hepatology, 52, 16, 10.1002/hep.23611 Zhu, 2001, Kinetics of hepadnavirus loss from the liver during inhibition of viral DNA synthesis, J Virol, 75, 311, 10.1128/JVI.75.1.311-322.2001 Dandri, 2000, Increased hepatocyte turnover and inhibition of woodchuck hepatitis B virus replication by adefovir in vitro do not lead to reduction of the closed circular DNA, Hepatology, 32, 139, 10.1053/jhep.2000.8701 Laras, 2006, Intrahepatic levels and replicative activity of covalently closed circular hepatitis B virus DNA in chronically infected patients, Hepatology, 44, 694, 10.1002/hep.21299 Volz, 2007, Impaired intrahepatic hepatitis B virus productivity contributes to low viremia in most HBeAg-negative patients, Gastroenterology, 133, 843, 10.1053/j.gastro.2007.06.057 Werle-Lapostolle, 2004, Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy, Gastroenterology, 126, 1750, 10.1053/j.gastro.2004.03.018 Lebossé, 2017, Intrahepatic innate immune response pathways are downregulated in untreated chronic hepatitis B, J Hepatol, 66, 897, 10.1016/j.jhep.2016.12.024 Gordon, 2013, Efficacy of tenofovir disoproxil fumarate at 240 weeks in patients with chronic hepatitis B with high baseline viral load: Hepatology, Hepatology, 58, 505, 10.1002/hep.26277 Moraleda, 1997, Lack of effect of antiviral therapy in nondividing hepatocyte cultures on the closed circular DNA of woodchuck hepatitis virus, J Virol, 71, 9392, 10.1128/jvi.71.12.9392-9399.1997 Burdette, 2019, PS-150-Evidence for the presence of infectious virus in the serum from chronic hepatitis B patients suppressed on nucleos (t)ide therapy with detectable but not quantifiable HBV DNA, J Hepatol, 70, e95, 10.1016/S0618-8278(19)30168-9 Huang, 2021, Rapid turnover of hepatitis B virus covalently closed circular DNA indicated by monitoring emergence and reversion of signature-mutation in treated chronic hepatitis B patients, Hepatology, 73, 41, 10.1002/hep.31240 Ko, 2018, Hepatitis B virus genome recycling and de novo secondary infection events maintain stable cccDNA levels, J Hepatol, 69, 1231, 10.1016/j.jhep.2018.08.012 Guo, 2000, Apoptosis and regeneration of hepatocytes during recovery from transient hepadnavirus infections, J Virol, 74, 1495, 10.1128/JVI.74.3.1495-1505.2000 Summers, 2003, Hepatocyte turnover during resolution of a transient hepadnaviral infection, Proc Natl Acad Sci, 100, 11652, 10.1073/pnas.1635109100 Mason, 2005, Clonal expansion of hepatocytes during chronic woodchuck hepatitis virus infection, Proc Natl Acad Sci, 102, 1139, 10.1073/pnas.0409332102 Guidotti, 1999, Viral clearance without destruction of infected cells during acute HBV infection, Science, 284, 825, 10.1126/science.284.5415.825 Wieland, 2004, Expansion and contraction of the hepatitis B virus transcriptional template in infected chimpanzees, Proc Natl Acad Sci USA, 101, 2129, 10.1073/pnas.0308478100 Murray, 2005, Dynamics of hepatitis B virus clearance in chimpanzees, Proc Natl Acad Sci, 102, 17780, 10.1073/pnas.0508913102 Allweiss, 2018, Proliferation of primary human hepatocytes and prevention of hepatitis B virus reinfection efficiently deplete nuclear cccDNA in vivo, Gut, 67, 542, 10.1136/gutjnl-2016-312162 Li, 2017, Distribution of hepatitis B virus nuclear DNA, J Virol, 92 Addison, 2002, Half-life of the duck hepatitis B virus covalently closed circular DNA pool in vivo following inhibition of viral replication, J Virol, 76, 6356, 10.1128/JVI.76.12.6356-6363.2002 Murray, 2015, In silico single cell dynamics of hepatitis B virus infection and clearance, J Theor Biol, 366, 91, 10.1016/j.jtbi.2014.11.020 Goyal, 2018, The dynamics of integration, viral suppression and cell-cell transmission in the development of occult Hepatitis B virus infection, J Theor Biol, 455, 269, 10.1016/j.jtbi.2018.06.020 Goyal, 2016, Modelling the impact of cell-to-cell transmission in hepatitis B virus, PloS One, 11, 10.1371/journal.pone.0161978 Goyal, 2019, Within-host mathematical models of hepatitis B virus infection: past, present, and future, Curr Opin Syst Biol, 18, 27, 10.1016/j.coisb.2019.10.003 Charre, 2019, Non-invasive biomarkers for chronic hepatitis B virus infection management, Antivir Res, 169, 104553, 10.1016/j.antiviral.2019.104553 Cai, 2012, Identification of disubstituted sulfonamide compounds as specific inhibitors of hepatitis B virus covalently closed circular DNA formation, Antimicrob Agents Chemother, 56, 4277, 10.1128/AAC.00473-12 Liu, 2016, Identification of hydrolyzable tannins (punicalagin, punicalin and geraniin) as novel inhibitors of hepatitis B virus covalently closed circular DNA, Antiviral Res, 134, 97, 10.1016/j.antiviral.2016.08.026 Wang, 2019, PS-074-A first-in-class orally available HBV cccDNA destabilizer ccc_R08 achieved sustainable HBsAg and HBV DNA suppression in the HBV circle mouse model through elimination of cccDNA-like molecules in the mouse liver, J Hepatol, 70, e48, 10.1016/S0618-8278(19)30086-6 Cradick, 2010, Zinc-finger nucleases as a novel therapeutic strategy for targeting hepatitis B virus DNAs, Mol Ther, 18, 947, 10.1038/mt.2010.20 Bloom, 2013, Inactivation of hepatitis B virus replication in cultured cells and in vivo with engineered transcription activator-like effector nucleases, Mol Ther, 21, 1889, 10.1038/mt.2013.170 2020, 2020 ASGCT annual meeting abstracts, Mol Ther, 28, 1, 10.1016/j.ymthe.2020.04.019 Jinek, 2012, A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity, Science, 337, 816, 10.1126/science.1225829 Ran, 2013, Genome engineering using the CRISPR-Cas9 system, Nat Protoc, 8, 2281, 10.1038/nprot.2013.143 Ledford, 2020, Pioneers of revolutionary CRISPR gene editing win chemistry Nobel, Nature, 586, 346, 10.1038/d41586-020-02765-9 Bloom, 2018, Gene therapy for chronic HBV—can we eliminate cccDNA?, Genes, 9, 207, 10.3390/genes9040207 Verkuijl, 2019, The influence of eukaryotic chromatin state on CRISPR–Cas9 editing efficiencies, Curr Opin Biotechnol, 55, 68, 10.1016/j.copbio.2018.07.005 Isaac, 2016, Nucleosome breathing and remodeling constrain CRISPR-Cas9 function, ELife, 5, 10.7554/eLife.13450 Martinez, 2020, SAT376 - targeting hepatitis B virus with CRISPR/Cas9 approach, J Hepatol, 73, S841, 10.1016/S0168-8278(20)32126-7 Stone, 2021, CRISPR-Cas9 gene editing of hepatitis B virus in chronically infected humanized mice, Mol Ther - Methods Clin Dev, 20, 258, 10.1016/j.omtm.2020.11.014 Simhadri, 2018, Prevalence of pre-existing antibodies to CRISPR-associated nuclease Cas9 in the USA population, Mol Ther - Methods Clin Dev, 10, 105, 10.1016/j.omtm.2018.06.006 Charlesworth, 2019, Identification of preexisting adaptive immunity to Cas9 proteins in humans, Nat Med, 25, 249, 10.1038/s41591-018-0326-x Li, 2020, AAV-CRISPR gene editing is negated by pre-existing immunity to Cas9, Mol Ther, 28, 1432, 10.1016/j.ymthe.2020.04.017 Rouet, 2018, Engineering CRISPR-Cas9 RNA–protein complexes for improved function and delivery, CRISPR J, 1, 367, 10.1089/crispr.2018.0037 Kosicki, 2018, Repair of double-strand breaks induced by CRISPR–Cas9 leads to large deletions and complex rearrangements, Nat Biotechnol, 36, 765, 10.1038/nbt.4192 Rees, 2018, Base editing: precision chemistry on the genome and transcriptome of living cells, Nat Rev Genet, 19, 770, 10.1038/s41576-018-0059-1 Anzalone, 2020, Genome editing with CRISPR–Cas nucleases, base editors, transposases and prime editors, Nat Biotechnol, 38, 824, 10.1038/s41587-020-0561-9 Yang, 2020, Permanent inactivation of HBV genomes by CRISPR/Cas9-Mediated non-cleavage base editing, Mol Ther - Nucleic Acids, 20, 480, 10.1016/j.omtn.2020.03.005 Yu, 2020, Cytosine base editors with minimized unguided DNA and RNA off-target events and high on-target activity, Nat Commun, 11, 2052, 10.1038/s41467-020-15887-5 Love, 2012, Biochemical analysis of hypermutation by the deoxycytidine deaminase APOBEC3A, J Biol Chem, 287, 30812, 10.1074/jbc.M112.393181 Stenglein, 2010, APOBEC3 proteins mediate the clearance of foreign DNA from human cells, Nat Struct Mol Biol, 17, 222, 10.1038/nsmb.1744 Lucifora, 2014, Specific and nonhepatotoxic degradation of nuclear hepatitis B virus cccDNA, Science, 343, 1221, 10.1126/science.1243462 Nair, 2018, Asymmetric modification of hepatitis B virus (HBV) genomes by an endogenous cytidine deaminase inside HBV cores informs a model of reverse transcription, J Virol, 92, 10.1128/JVI.02190-17 Gehring, 2011, Engineering virus-specific T cells that target HBV infected hepatocytes and hepatocellular carcinoma cell lines, J Hepatol, 55, 103, 10.1016/j.jhep.2010.10.025 Bertoletti, 2015, T cell receptor-therapy in HBV-related hepatocellularcarcinoma, OncoImmunology, 4, 10.1080/2162402X.2015.1008354 Koh, 2018, Nonlytic lymphocytes engineered to express virus-specific T-cell receptors limit HBV infection by activating APOBEC3, Gastroenterology, 155, 10.1053/j.gastro.2018.03.027 Suspene, 2005, Extensive editing of both hepatitis B virus DNA strands by APOBEC3 cytidine deaminases in vitro and in vivo, Proc Natl Acad Sci, 102, 8321, 10.1073/pnas.0408223102 Seeger, 2016, Complete spectrum of CRISPR/Cas9-induced mutations on HBV cccDNA, Mol Ther, 24, 1258, 10.1038/mt.2016.94 Hilton, 2015, Epigenome editing by a CRISPR-Cas9-based acetyltransferase activates genes from promoters and enhancers, Nat Biotechnol, 33, 510, 10.1038/nbt.3199 Roberts, 2013, An APOBEC cytidine deaminase mutagenesis pattern is widespread in human cancers, Nat Genet, 45, 970, 10.1038/ng.2702 Gao, 2009, Tripartite motif-containing 22 inhibits the activity of hepatitis B virus core promoter, which is dependent on nuclear-located RING domain, Hepatology, 50, 424, 10.1002/hep.23011 Palumbo, 2015, IL6 inhibits HBV transcription by targeting the epigenetic control of the nuclear cccDNA minichromosome, PloS One, 10 Isorce, 2016, Antiviral activity of various interferons and pro-inflammatory cytokines in non-transformed cultured hepatocytes infected with hepatitis B virus, Antiviral Res, 130, 36, 10.1016/j.antiviral.2016.03.008 Lin, 2003, IL-4 suppresses the expression and the replication of hepatitis B virus in the hepatocellular carcinoma cell line Hep3B, J Immunol, 171, 4708, 10.4049/jimmunol.171.9.4708 Hong, 2012, Transforming growth factor-β1 suppresses hepatitis B virus replication by the reduction of hepatocyte nuclear factor-4α expression, PloS One, 7, 10.1371/journal.pone.0030360 Mitra, 2018, Host functions used by hepatitis B virus to complete its life cycle: implications for developing host-targeting agents to treat chronic hepatitis B, Antiviral Res, 158, 185, 10.1016/j.antiviral.2018.08.014 Yu, 2018, AGK2, A SIRT2 inhibitor, inhibits hepatitis B virus replication in vitro and in vivo, Int J Med Sci, 15, 1356, 10.7150/ijms.26125 Gilmore, 2017, Antiviral activity of GS-5801, a liver-targeted prodrug of a lysine demethylase 5 inhibitor, in a hepatitis B virus primary human hepatocyte infection model, J Hepatol, 66, S690, 10.1016/S0168-8278(17)31855-X Zhang, 2017, PRMT5 restricts hepatitis B virus replication through epigenetic repression of covalently closed circular DNA transcription and interference with pregenomic RNA encapsidation, Hepatology, 66, 398, 10.1002/hep.29133 Fernández-Barrena, 2020, Epigenetics in hepatocellular carcinoma development and therapy: the tip of the iceberg, JHEP Rep, 2, 100167, 10.1016/j.jhepr.2020.100167 Kornyeyev, 2019, Spatiotemporal analysis of hepatitis B virus X protein in primary human hepatocytes, J Virol, 93, 10.1128/JVI.00248-19 Allweiss, 2021, Therapeutic shutdown of HBV transcripts promotes reappearance of the SMC5/6 complex and silencing of the viral genome in vivo, Gut Xirong, 2014, Hepatitis B virus can be inhibited by DNA methyltransferase 3a via specific zinc-finger-induced methylation of the X promoter, Biochem Mosc, 79, 111, 10.1134/S0006297914020047 Sekiba, 2019, Inhibition of HBV transcription from cccDNA with nitazoxanide by targeting the HBx–DDB1 interaction, Cell Mol Gastroenterol Hepatol, 7, 297, 10.1016/j.jcmgh.2018.10.010 Sekiba, 2019, Pevonedistat, a neuronal precursor cell-expressed developmentally down-regulated protein 8–activating enzyme inhibitor, is a potent inhibitor of hepatitis B virus, Hepatology, 69, 1903, 10.1002/hep.30491 Fanning, 2019, Therapeutic strategies for hepatitis B virus infection: towards a cure, Nat Rev Drug Discov, 18, 827, 10.1038/s41573-019-0037-0 Yuen, 2020, Antiviral activity and safety of the hepatitis B core inhibitor ABI-H0731 administered with a nucleos(t)ide reverse transcriptase inhibitor in patients with HBeAg-positive chronic hepatitis B infection in a long-term extension study, J Hepatol, 73, S140, 10.1016/S0168-8278(20)30790-X Gane, 2020, Short-term treatment with RNA interference therapy, JNJ-3989, results in sustained hepatitis B surface antigen supression in patients with chronic hepatitis B receiving nucleos(t)ide analogue treatment, J Hepatol, 73, S20, 10.1016/S0168-8278(20)30597-3 2020, Oral abstracts, Hepatology, 72, 1A, 10.1002/hep.31578 Yuen, 2020, Hepatitis B virus (HBV) surface antigen (HBsAg) inhibition with isis 505358 in chronic hepatitis B (CHB) patients on stable nucleos (t)ide analogue (NA) regimen and in NA-naive CHB patients: phase 2a, randomized, double-blind, placebo-controlled study, J Hepatol, 73, S49, 10.1016/S0168-8278(20)30646-2 Yuen, 2019, First clinical experience with RNA interference-based triple combination therapy in chronic hepatitis B: JNJ-3989, JNJ-6379 and a Nucleos (t) ide analogue, Hepatology, 70, 1489A Wedemeyer, 2020, 48 weeks of high dose (10 mg) bulevirtide as monotherapy or with peginterferon alfa-2a in patients with chronic HBV/HDV co-infection, J Hepatol, 73, S52, 10.1016/S0168-8278(20)30651-6 Bazinet, 2020, Safety and efficacy of 48 Weeks REP 2139 or REP 2165, tenofovir disoproxil, and pegylated interferon alfa-2a in patients with chronic HBV infection naïve to nucleos(t)ide therapy, Gastroenterology, 158, 2180, 10.1053/j.gastro.2020.02.058 Gane, 2020, Efficacy and safety of 24 weeks treatment with oral TLR8 agonist, selgantolimod, in virally-suppressed adult patients with chronic hepatitis B: a phase 2 study, J Hepatol, 73, S52, 10.1016/S0168-8278(20)30650-4 Michler, 2020, Knockdown of virus antigen expression increases therapeutic vaccine efficacy in high-titer hepatitis B virus carrier mice, Gastroenterology, 158, 10.1053/j.gastro.2020.01.032 Gane, 2019, Anti-PD-1 blockade with nivolumab with and without therapeutic vaccination for virally suppressed chronic hepatitis B: a pilot study, J Hepatol, 71, 900, 10.1016/j.jhep.2019.06.028 Maini, 2018, Defective T-cell immunity in hepatitis B virus infection: why therapeutic vaccination needs a helping hand, Lancet Gastroenterol Hepatol, 3, 192, 10.1016/S2468-1253(18)30007-4 Dandri, 2020, Epigenetic modulation in chronic hepatitis B virus infection, Semin Immunopathol, 42, 173, 10.1007/s00281-020-00780-6 Revill, 2019, A global scientific strategy to cure hepatitis B, Lancet Gastroenterol Hepatol, 4, 545, 10.1016/S2468-1253(19)30119-0